---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Drug interactions questions"
description: "Drug interactions questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What are the drug interactions with Kesimpta? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Drug interactions questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Drug interactions

<a id="kesimpta-drug-interactions"></a>

### What are the drug interactions with Kesimpta?

> “Concomitant usage of KESIMPTA with immunosuppressant drugs, including systemic corticosteroids, may increase the 
> risk of infection. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies 
> with KESIMPTA.”

Source: [KESIMPTA: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=7)

> “Ofatumumab does not share a common clearance pathway with chemical drugs that are metabolized by the cytochrome 
> P450 system or other drug-metabolizing enzymes. Additionally, there is no evidence that CD20 monoclonal antibodies are 
> involved in the regulation of the expression of drug-metabolizing enzymes. Interactions between KESIMPTA and other 
> medicinal products have not been investigated in formal studies.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
